Rohto Pharmaceutical has updated its medium- to long-term growth strategy on a rolling basis and newly set financial forecasts for fiscal 2031. The targets for fiscal 2031 are revenue of ¥464 billion, operating profit of ¥59.8 billion, an operating margin of 12.9%, an overseas sales ratio of 56% and a dividend payout ratio of 40%.
Based on the Rohto Group Medium- to Long-Term Growth Strategy 2025–2035, Rohto Pharmaceutical has reviewed its financial forecasts on a rolling basis and updated the forecast period to fiscal 2026 through fiscal 2031. It has consequently set out new financial forecasts with fiscal 2031 as the target year. The previously disclosed medium-term management targets had been set for fiscal 2030.
The main figures in the financial forecasts for fiscal 2031 are revenue of ¥464 billion, operating profit of ¥59.8 billion, an operating margin of 12.9%, an overseas sales ratio of 56% and a dividend payout ratio of 40%. Compared with previous forecasts, the period has been extended and the ratio targets have been updated.
The medium- to long-term strategy has three pillars: strengthening business profitability, deepening and expanding technological and product capabilities, and building the foundation for the medical business. Strengthening business profitability includes the global expansion of self-care and expansion into new fields. Deepening technological and product capabilities includes research into phytoscience materials, the introduction of supplements, gastrointestinal and post-treatment care through oral medicines and foods, and collaboration in the ophthalmology field.
Building the foundation for the medical business aims to establish a medical business foundation, while promoting the expansion of CDMO operations and product development and collaboration related to ophthalmology and dermatology. This update reflects the rolling application of the previous fiscal 2030 financial targets to fiscal 2031.